Navigation Links
Breakthrough research identifies how cells from pigs may cure diabetes
Date:9/12/2007

MINNEAPOLIS, Minn. Within three years, insulin-producing islet cells from pigs may be used in clinical trials on a path to finally cure insulin dependant diabetes.

This key finding was the discovery of Dr. Bernhard Hering, Scientific Director of the Diabetes Institute for Immunology & Transplantation at the University of Minnesota and his team, who documented their medical breakthrough in the prestigious scientific journal Nature Medicine in March of 2006.

On Thursday, September 20, at 10:00 a.m. CDT, Hering will present the latest research on pig islet xenotransplantation at the Diabetes Research and Wellness Foundation Symposium at the Hyatt Regency Minneapolis in Minneapolis, MN.

The symposium will be part of The Transplantation Societys 2007 Joint Conference (www.cts-ipita-ixa-2007.org), an international event that will unite the greatest innovators from three sections of the Transplantation Society the Cell Transplant Society (CTS), the International Pancreas and Islet Transplant Association (IPITA) and the International Xenotransplantation Association (IXA) for the first time in history. Hering also serves as the Joint Conference president.

Research has shown that the transplantation of islet cells, harvested from the pancreas of a pig, yields a long-term reversal of diabetes in monkeys, opening the path to unprecedented new opportunities for human patients with the disease. To oversee immunosuppression issues, researchers are now working to transplant porcine islets in an engineered pre-vascularized, cytoprotective and immune-privileged implantation site. This procedure has a number of advantages including:

  • Pigs will be able to provide unlimited islet tissue in a few years.

  • Pig islets from young disease-free donors are superior to cadaver human islets.

  • The actual risk of infectious disease transmission is lower with xenotransplantation of islets.

  • Bioengineering of islet implantation sites into a pre-vascularized, cytoprotective and immune-privileged site will allow for local and selective immunosuppression.

  • Promoting long-term survival of the porcine islet xenografts in humans.

As Hering and his team prepare to enter into clinical trials slated to commence within three years Spring Point Project (www.springpointproject.org), a non-profit organization, is helping to grow a population of medical grade pigs so that once the cure is realized, diabetes sufferers will find the treatment to be widely available and affordable.

Dr. Henk-Jan Schuurman, CEO of Spring Point Project, will moderate the Source Pigs for Xenotransplantation Trials Symposium on Saturday, September 15 at the Hyatt Regency Minneapolis, during the Joint Conference.

In order to have high health pigs available for clinical trials, Spring Point Project now operates a 21,000-square-foot biosecure facility in Western Wisconsin called the Diabetes Research and Wellness Foundation Islet Resource Facility. Inside, a team of highly skilled veterinarians and animal care staff is actively raising high health pigs in compliance with governmental regulations a charge that requires the pigs to be housed in an ultra clean biosecure environment, fed special food and given only purified water to drink and filtered air to breathe.

Continuing to populate our Islet Resource Facility brings us closer to meeting our ultimate goal of curing diabetes, Schuurman says. With the pigs that are currently housed in our biosecure facility, were already expediting the widespread availability of islet cell tissue so that an adequate supply of pig donors will be available for clinical islet cell transplantation trials using patients with diabetes.


'/>"/>

Contact: Molly Kersten
mkersten@r-p.com
419-241-2221
R/P Marketing Public Relations
Source:Eurekalert

Related biology news :

1. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
2. Breakthrough Microarray-based Technology for the Study of Cancer
3. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
4. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
5. MUHC researchers make cancer target breakthrough
6. Breakthrough isolating embryo-quality stem cells from blood
7. Breakthrough System for Understanding Ocean Plant Life Announced
8. Major breakthrough in the treatment of cancers and infectious diseases
9. Breakthrough: Scientists create worlds tiniest organic particles
10. Sciences Breakthrough of the Year: Watching evolution in action
11. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology: